Full Professor
Strategic program(s):
Biography
Marnix Lam (1975) studied Pharmaceutical sciences (passed with distinction) and Medicine at Utrecht University. He became a resident in Nuclear Medicine, respectively Radiology and finalized his PhD thesis (2009) on radionuclide therapy in prostate cancer patients with metastatic bone pain. This was followed by a two-year postdoctoral fellowship at Stanford University School of Medicine, USA. In 2016 he was appointed Professor of Nuclear Medicine.
Translational research in molecular medicine has been the scope of his scientific work, with a focus on oncology. Bringing new radiopharmaceuticals to clinical practice. This specifically resulted in the introduction of new oncological treatment modalities in the Netherlands, such as bone seeking radiopharmaceuticals for the palliation of metastatic bone pain (Sm-153-EDTMP, Re-188-HEDP) and radioembolization for treatment of hepatic malignancies (Y-90 and Ho-166 microspheres). Current research is focussed on dosimetry of therapeutic radiopharmaceuticals, image-guided treatment technology, alfa- and beta-emitting isotopes for therapeutic purposes, intra-arterial and intra-tumor treatment approaches, and radio-immunotherapy.
Research aim
With nuclear theranostics we aim to develop radiopharmaceuticals to improve the disease diagnosis and therapy, including clinical translation for direct impact. Disease areas of interest are (childhood) cancer, neurology and infectious diseases.
Go to groupResearch aim
To improve surveillance, diagnostics, treatment, and outcome for patients with primary liver tumors (hepatocellular carcinoma and cholangiocarcinoma) by interdisciplinary and (inter-)national collaborative research
Go to group2021 - Research grant from ‘Zorginstituut, Veelbelovende zorg’: SIRT with 166Ho-microspheres in elderly and fragile patients with previously untreated unresectable liver-only metastases of colorectal cancer, CAIRO7 study of the Dutch Colorectal Cancer Group (DCCG)
2021 - Research grant from Quirem: clinical research on the safety and efficacy of holmium-166 (166Ho)-microspheres radioembolization in patients with hepatic malignancies.
2021 - Research grant from Terumo: Individualized dosimetry for holmium-166 (166Ho)-radioembolization in patients with unresectable hepatocellular carcinoma; a multi-center, interventional, non-randomized, non-comparative, open label, early phase II study: iHEPAR.
2021 - Research grant from Terumo: The RALLY study: Dose finding study for unilobar radiation lobectomy using holmium-166 (166H0)-microspheres to improve resectability in patients with HCC .
2020 - Research grant from Boston Scientific: Hepatic glass yttrium-90 (90Y)-microspheres radioembolization.
2020 - Awarded CVIR Editors’ Medal for 2020: Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity. Braat, A.J.A.T., Kappadath, S.C., Ahmadzadehfar, H. et al. Cardiovasc Intervent Radiol (2019) 42(3).
2020 - Awarded Editors’ Choice Paper and top 10% downloaded papers in Medical Physics: Kunnen B et al. Feasibility of imaging 90Y microspheres at diagnositc activity levels for hepatic radioembolization treatment planning. Med Phys.
2019 - Alavi-Mandell award for best publication in Journal of Nuclear Medicine: Efficacy of Radioembolization with 166Ho-Microspheres in Salvage Patients with Liver Metastases: A Phase 2 Study. J Nucl Med. 2018 Apr;59(4):582-588.
2018 - Research grant from the Dutch Cancer Society (KWF): Diagnostic accuracy of Gallium-68 PSMA PET/CT in primary staging of prostate cancer
2018 - Research grant from NWO Industrial Doctorates program: Advanced dosimetry for personalized radioembolization treatment (ADOPT)
2018 - Research grant from BTG / Boston Scientific: LUMI DEBIRI and TheraSphere for treatment of metastatic colorectal cancer (DEBIRY)
2018 - Research grant from Health Holland program: Intra-arterial lutetium-177-dotatate for treatment of patients with neuroendocrine tumor liver metastases
2017 - Alavi-Mandell award for best publication in Journal of Nuclear Medicine: Insights into the dose-response relationship of radioembolization with resin yttrium-90 microspheres: a prospective cohort study in patients with colorectal cancer liver metastases. J Nucl Med. 2016 Jul;57(7):1014-9.
2016 - Research grant from the Dutch Cancer Society (KWF): Holmium-166 microspheres for radioembolization in HCC patients: new generation microspheres for individualized treatment
2016 Alavi-Mandell award for best publication in Journal of Nuclear Medicine: Safety of a Scout Dose Preceding Hepatic Radioembolization with 166Ho Microspheres. J Nucl Med. 2015 Jun;56(6):817-23.
2016 - Alavi-Mandell award for best publication in Journal of Nuclear Medicine: Impact of Personal Characteristics and Technical Factors on Quantification of Sodium 18F-Fluoride Uptake in Human Arteries: Prospective Evaluation of Healthy Subjects. J Nucl Med. 2015 Oct;56(10):1534-40.
2016 - Appointed as full professor of Nuclear Medicine at the University of Utrecht, The Netherlands
2014 - Research grant from Alpe d’Huzes / Dutch Cancer Society (KWF): Holmium micro-brachytherapy: an innovative intratumoral treatment modality in head and neck cancer
2014 - Appointed as honorary professor at the medical school of the People’s Liberation Army General Hospital and Military University, Beijing, China
2014 - CIRSE Award of Excellence and Innovation in Interventional Radiology
2010 - Research grant from the Dutch Cancer Society (KWF): translational research in oncology
Adviseur, spreker - Advies, spreken op (inter)nationale gelegenheden, samenwerking op gebied van klinisch onderzoek - Novartis
Scientific Advisory Board - Wetenschappelijk advies - OncoSil Medical Limited
Consultant - Advieswerk - Becton Dickinson
Voorzitter wetenschappelijke adviesraad NRG Pallas - Voorzitter wetenschappelijke adviesraad NRG Pallas - NRG Pallas
Adviseur, spreker - Advies, spreker op (inter)nationale gelegenheden, wetenschappelijke samenwerking - Terumo/Quirem Medical B.V.
Adviseur - Advies, wetenschappelijke samenwerking - Boston Scientific
